Australia Diabetes Devices - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The australia diabetes devices market size was valued at USD 721.44 million in 2025 and estimated to grow from USD 738.97 million in 2026 to reach USD 832.6 million by 2031, at a CAGR of 2.43% during the forecast period (2026-2031). This report Segments the Industry Into Device Type (Management Devices and Monitoring Devices), by End User (Home-Care Settings, Hospitals, and More), by Diabetes Type (Type 1 Diabetes, Type 2 Diabetes and Gestational Diabetes), by Technology (Invasive Systems, Minimally Invasive Systems, and Non-Invasive Systems). The Market Sizes and Forecasts are Provided in Terms of Value (USD).

Australia Diabetes Devices Market Trends and Insights

Expansion of CGM reimbursement via NDSS & private health funds

National reimbursement initiatives have transformed the Australia diabetes devices market by removing upfront cost barriers for real-time CGM. The NDSS CGM Initiative, which subsidises CGM for every person with type 1 diabetes, lifted utilisation from 5% to as high as 79% among eligible users. Insurers have complemented this policy, funding sensors for high-risk pregnancies and paediatric cohorts. Evidence from cost-utility studies shows an incremental cost-effectiveness ratio of AUD 39,518 per quality-adjusted life-year versus self-funded use. Heightened public coverage has also stimulated manufacturer competition, prompting quicker rollouts of next-generation sensors with longer wear time and factory calibration.

Escalating diabetes prevalence driving device demand

Diagnosed diabetes cases reached 1.3 million in 2025, with an additional 500,000 people undiagnosed, underscoring unmet monitoring needs. Type 2 diabetes accounts for seven in ten cases and is rising fastest in lower-income and Indigenous populations. The Australia diabetes devices market benefits directly, as primary-care guidelines encourage earlier CGM initiation for complex type 2 profiles. Advocacy groups are lobbying to extend NDSS subsidies from type 1 to insulin-requiring type 2 cohorts, a policy change that could lift sensor volumes by a further 20%.

High out-of-pocket cost of pump consumables outside insurance cover

While public and private schemes offset sensor costs, many Australians still pay USD 4,600-USD 6,600 equivalent for pump consumables across a four-year warranty cycle. Parliamentary modelling shows universal pump subsidies would require up to AUD 749 million over forward estimates. Price pressures deter uptake among low-income adults, contributing to slower penetration of automated insulin delivery systems beyond paediatric segments. The Australia diabetes devices market therefore faces a ceiling effect until funding parity with CGM is achieved.

Other drivers and restraints analyzed in the detailed report include:

• Rapid uptake of digital health and telehealth services
• Local R&D for non-invasive CGM
• Limited interoperability between imported pumps & local apps

Segment Analysis

Monitoring devices generated 56.62% of Australia diabetes devices market revenue in 2025 and represent the anchor segment. Strong NDSS backing vaulted CGM penetration, making sensors routine even in primary care. At USD 408.6 million, the monitoring slice of the Australia diabetes devices market size benefits from frequent sensor replacement that ensures recurring revenue. The early-2025 addition of Dexcom G7 and FreeStyle Libre 2 Plus reinforced competitive intensity, with both brands offering twelve-hour warm-up times and predictive alert algorithms that satisfy national clinical guidelines.

Management devices earned the remaining share but are expanding at a 3.01% CAGR, the fastest within the portfolio. Evidence from multi-centre Queensland trials indicates that automated insulin delivery improves time-in-range by 15 percentage points, translating to lower complication risk and stronger payer support. If the proposed universal pump subsidy passes Parliament by 2026, uptake could propel the therapy segment to USD 392.4 million by 2031, thereby shrinking the gap between monitoring and management categories within the Australia diabetes devices market.

Hospital systems contributed 47.85% of Australia diabetes devices market share in 2025 because they are the primary enrolment point for pump initiation, sensor training, and acute complication management. Large metropolitan teaching hospitals run specialised diabetes technology clinics that standardise device selection protocols. In rural regions, district hospitals rely on visiting nurse educators, yet still dominate procurement budgets, reinforcing hospital grip on the supply chain of the Australia diabetes devices market.

Home-care settings are climbing at a 2.91% CAGR as telehealth compresses geographic constraints. A national survey showed 64% of sensor users now transmit real-time glucose data to clinicians from home, reducing routine clinic visits. Private insurers are piloting bundled payment models that provide sensors, smart pens, and virtual coaching under a single premium. This shift encourages longer-term adherence, suggesting home-care could surpass 35.00% revenue share of the Australia diabetes devices market by 2031.

Complete Report Scope:

• By Device Type
  • Management Devices
    • Insulin Pumps
      • Pump Device
      • Reservoir
      • Infusion Set
    • Insulin Syringes
    • Cartridges in Re-usable Pens
    • Disposable Insulin Pens
    • Jet Injectors
  • Monitoring Devices
    • Self-Monitoring Blood Glucose
      • Glucometer Devices
      • Test Strips
      • Lancets
    • Continuous Glucose Monitoring
      • Sensors
      • Durables / Transmitters
    • Emerging Non-Invasive CGM Prototypes
• By End User
  • Home-Care Settings
  • Hospitals
  • Specialty Diabetes Clinics
  • Community & Retail Pharmacies (Point-of-Care)
• By Diabetes Type
  • Type 1 Diabetes
  • Type 2 Diabetes
  • Gestational Diabetes
• By Technology
  • Invasive Systems
  • Minimally Invasive Systems
  • Non-Invasive Systems

List of Companies Covered in this Report:

• Abbott Laboratories
• Medtronic
• Dexcom
• Roche
• Novo Nordisk
• Sanofi
• Eli Lilly and Company
• Lifescan
• Ascensia
• Insulet
• Ypsomed
• Tandem Diabetes Care
• Senseonics
• B. Braun
• Arkray
• AgaMatrix
• Terumo

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support